Adlbrecht, C. and Wild, C. (2007): [Photoselective vaporisation of the prostate in men with benign prostatic hyperplasia. HTA in hospitals]. Decision Support Document 01.
Breuer, J. and Joppi, R. and Poggiani, C. and Polkowska, M. and Nachtnebel, A. (2014): Radium-223 dichloride (Xofigo®) for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease. DSD: Horizon Scanning in Oncology 44.
Breuer, J. and Nachtnebel, A. (2013): Enzalutamide (Xtandi®) for patients with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy . DSD: Horizon Scanning in Oncology 37.
Erdos, J. and Fischer, S. (2018): High-intensity focused ultrasound for the treatment of prostate cancer. 1st Update 2018. Decision Support Document 37/ Update 2018.
Fischer, S. and Kisser, A. (2015): Robot-assisted surgery: A systematic review of effectiveness and safety for elected indications and accumulating costs. HTA-Projektbericht 84.
Geiger-Gritsch, S. (2008): [Testosterone-substitution for androgen deficiency in the ageing men]. HTA-Newsletter 66: 2.
Groessmann, N. (2020): Darolutamide (Nubeqa®) in nonmetastatic, castration-resistant prostate cancer (nmCRPC). Oncology Fact Sheet Nr. 2.
Mad, P. (2007): [Robotic surgery in urology: Prostate interventions]. HTA-Newsletter 54: 4.
Mathis, S. (2007): [Interstitial brachytherapy in the treatment of localised prostate cancer]. HTA-Newsletter 57: 4.
Nachtnebel, A. (2011): Second-line chemotherapy with cabazitaxel (Jevtana®) for the treatment of castration-resistant metastatic prostate cancer. DSD: Horizon Scanning in Oncology 16.
Nachtnebel, A. and Püntmann, I. (2011): Abiraterone acetate (Zytiga™) as 2nd-line therapy for the treatment of metastatic castration resistant prostate cancer after docetaxel therapy. DSD: Horizon Scanning in Oncology 20.
Rothschedl, E. (2019): Enzalutamide (Xtandi®) in addition to standard first-line therapy in men with metastatic hormone-sensitive prostate cancer (mHSPC). DSD: Horizon Scanning in Oncology 90.
Rothschedl, E. (2019): Darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC). DSD: Horizon Scanning in Oncology 88.
Rothschedl, E. (2018): Enzalutamide (Xtandi®) in patients with nonmetastatic, castration-resistant prostate cancer (CRPC). DSD: Horizon Scanning in Oncology 84.
Schmidt, L. and Lohr, P. and Wild, C. (2018): Stereotactic radiotherapy, proton therapy and irreversible electroporation for the treatment of localised prostate cancer. HTA-Projektbericht 107.
Stanak, M. and Grössman, N. and Strohmaier, C. (2019): 177Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer . Decision Support Document 118.
Vreugdenburg, Thomas and Wild, C. (2017): Prostate artery embolisation for benign prostatic hyperplasia. Decision Support Document 105.
Warmuth, M. and Johansson, T. (2010): High-intensity focussed ultrasound (HIFU) for the treatment of prostate cancer. Decision Support Document 37.
Wild, C. (2003): [Cryosurgery for prostate cancer]. HTA-Newsletter 23: 2.
Wild, C. (2001): [Brachytherapy for prostate cancer]. HTA-Newsletter 02: 3.
Wild, C. and Adlbrecht, C. (2007): [Laser vaporisation of benign prostatic hyperplasia]. HTA-Newsletter 56: 2.